FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) mechanisms to tackle the root causes of obesity. It suppresses appetite and reduces caloric intake, making it particularly effective for individuals whose OSA symptoms are exacerbated by excess weight.
Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea
Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and Drug Administration approval last month.
Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment costs about $1,000 a month without insurance.
Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss.
Medicare To Cover Eli Lilly's Weight Loss Drug Zepbound For Obstructive Sleep Apnea Treatment
Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, reducing apnea events by 62.8%.
Zepbound Approved for Obstructive Sleep Apnea in Patients With Obesity
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
You can't cure sleep apnea but you can manage it — doctors explain how
Try a single issue or save on a subscription Issues delivered straight to your door or device ...
Verywell Health on MSN10h
Cheese Lovers Might Be Less Likely to Have This Sleep Problem, Study Finds
New research suggests that cheese may help reduce sleep apnea risk, but that doesn't mean cheese is a sleep aid ...
Zawya19h
FDA approves Tirzepatideas: The first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
Averaging up to 20% of weight loss, adults taking Tirzepatide had at least 25 fewer breathing interruptions each hour as they ...
New imaging technique could transform obstructive sleep apnea diagnosis
Obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent airway blockages during sleep, leading ...
Rolling Out4d
How a sleep mask for apnea reduces high blood pressure risk
Sleep apnea affects millions globally, often lurking undetected until it begins impacting overall health. While high blood ...
Healthline4d
Is It Sleep Apnea or Just Loud Snoring?
It usually doesn’t interrupt breathing but can disturb others nearby and is often linked to obstructive sleep apnea. Loud snoring and sleep apnea share several risk factors. While snoring ...
Impacts1d
What a Home Sleep Study Reveals
Sleep apnea affects millions of people worldwide and prevents them from getting quality sleep. It negatively affects patients ...
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – – Obstructive ...